An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Canadian Cancer Trials Group
Summary
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Description
This study is being conducted to determine if this approach is better or worse than the standard of care for ovarian cancer. The standard of care is defined as care most people get for ovarian cancer.
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * This study will enroll women with platinum resistant high grade serous ovarian cancer. * This study is open to minorities as appropriate but is not designed to measure differences in intervention effects. * All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment. Additional Criteria To Be Met Prior To Sub-study Enrollment All pati…
Interventions
- DrugDurvalumab
1500mg IV, 60 min day 1 every 4 weeks
- DrugBA3011
IV
- DrugBA3021
IV
- DrugENB003
IV
- DrugToripalimab
IV
Locations (7)
- The University of Chicago Medical CenterChicago, Illinois
- BCCA - KelownaKelowna, British Columbia
- BCCA - VancouverVancouver, British Columbia
- Odette Cancer CentreToronto, Ontario
- University Health NetworkToronto, Ontario
- CHUM-Centre Hospitalier de l'Universite de MontrealMontreal, Quebec